BACKGROUND: Treatment options for relapsed/refractory ALL in adult patients remain challenging. Annamycin is a highly lipophilic form of the anthracycline doxorubicin with the ability to bypass multidrug resistance mechanisms of cellular drug resistance. PATIENTS AND METHODS: We performed a phase I/II multicenter, open-label, study to determine the maximally tolerated dose (MTD) of nanomolecular liposomal annamycin in adult patients with refractory ALL. RESULTS: Thirty-one patients were enrolled; the MTD was determined to be 150 mg/m(2)/d for 3 days. Other than tumor lysis syndrome, there were 3 grade 3 mucositis which comprised the MTD determination. There was also 1 case each of grade 3 diarrhea, typhlitis, and nausea. After determining the MTD, a 10-patient phase IIA trial was conducted. Eight of the patients completed 1 cycle of the 3 days of treatment at the MTD. Of these, 5 (62%) had an efficacy signal with complete clearing of circulating peripheral blasts. Three of these subjects also cleared bone marrow blasts with 1 subsequently proceeding onto successful stem cell transplantation. CONCLUSION: Single-agent nanomolecular liposomal annamycin appears to be well tolerated, and shows evidence of clinical activity as a single agent in refractory adult ALL.
BACKGROUND: Treatment options for relapsed/refractory ALL in adult patients remain challenging. Annamycin is a highly lipophilic form of the anthracycline doxorubicin with the ability to bypass multidrug resistance mechanisms of cellular drug resistance. PATIENTS AND METHODS: We performed a phase I/II multicenter, open-label, study to determine the maximally tolerated dose (MTD) of nanomolecular liposomal annamycin in adult patients with refractory ALL. RESULTS: Thirty-one patients were enrolled; the MTD was determined to be 150 mg/m(2)/d for 3 days. Other than tumor lysis syndrome, there were 3 grade 3 mucositis which comprised the MTD determination. There was also 1 case each of grade 3 diarrhea, typhlitis, and nausea. After determining the MTD, a 10-patient phase IIA trial was conducted. Eight of the patients completed 1 cycle of the 3 days of treatment at the MTD. Of these, 5 (62%) had an efficacy signal with complete clearing of circulating peripheral blasts. Three of these subjects also cleared bone marrow blasts with 1 subsequently proceeding onto successful stem cell transplantation. CONCLUSION: Single-agent nanomolecular liposomal annamycin appears to be well tolerated, and shows evidence of clinical activity as a single agent in refractory adult ALL.
Authors: U Consoli; W Priebe; Y H Ling; R Mahadevia; M Griffin; S Zhao; R Perez-Soler; M Andreeff Journal: Blood Date: 1996-07-15 Impact factor: 22.113
Authors: D J Booser; R Perez-Soler; P Cossum; L Esparza-Guerra; Q P Wu; Y Zou; W Priebe; G N Hortobagyi Journal: Cancer Chemother Pharmacol Date: 2000 Impact factor: 3.333
Authors: D Russo; P P Piccaluga; M Michieli; T Michelutti; G Visani; L Gugliotta; A Bonini; I Pierri; M Gobbi; M Tiribelli; R Fanin; S Piccolrovazzi; M Baccarani Journal: Ann Hematol Date: 2002-08-27 Impact factor: 3.673
Authors: Agostino Tafuri; Chiara Gregorj; Maria T Petrucci; Maria R Ricciardi; Marco Mancini; Giuseppe Cimino; Cristina Mecucci; Alessandra Tedeschi; Giuseppe Fioritoni; Felicetto Ferrara; Francesco Di Raimondo; Eugenio Gallo; Vincenzo Liso; Francesco Fabbiano; Nicola Cascavilla; Giovanni Pizzolo; Andrea Camera; Fabrizio Pane; Francesco Lanza; Daniela Cilloni; Luciana Annino; Antonella Vitale; Maria L Vegna; Marco Vignetti; Robin Foà; Franco Mandelli Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: Daniel J Booser; Francisco J Esteva; Edgardo Rivera; Vicente Valero; Laura Esparza-Guerra; Waldemar Priebe; Gabriel N Hortobagyi Journal: Cancer Chemother Pharmacol Date: 2002-05-21 Impact factor: 3.333
Authors: Lisa Sercombe; Tejaswi Veerati; Fatemeh Moheimani; Sherry Y Wu; Anil K Sood; Susan Hua Journal: Front Pharmacol Date: 2015-12-01 Impact factor: 5.810